Navigation Links
Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Date:7/8/2008

armasset.com">kurt.leutzinger@pharmasset.com

Office: +1 (609) 613-4110

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that Clevudine will not demonstrate any additive antiviral benefit in combination with tenofovir in the head-to-head study, the risk that Clevudine will not demonstrate superiority over Hepsera in Clevudine's ongoing Phase 3 registration study, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.

Viread and Hepsera are registered trademarks of Gilead Sciences, Inc.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Receives Notice of Allowance
2. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
3. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
4. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
5. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
8. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
9. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
10. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... and MELBOURNE, Australia , ... Nexvet Biopharma today announced the appointments of Dr. ... McCracken D.V.M ., M.S., to its Board of Directors. ... Medical Affairs Finance at Genentech and Chief Financial Officer ... served as Vice President and Global Head of Business ...
(Date:9/18/2014)... JOLLA, Calif. , Sept. 18, 2014 /PRNewswire/ ... RGLS ), a biopharmaceutical company leading the discovery ... today it has initiated its ATHENA natural history ... a life-threatening genetic kidney disease with no approved ... the natural decline of renal function markers such ...
(Date:9/18/2014)... days before the government of Sierra Leone ... Ebola, World Vision will begin a massive delivery of 200 ... McKesson, the largest healthcare services company in ... Medical-Surgical donated four million pairs of latex gloves – enough ... needs for the next five months* – to ...
Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 2World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 3World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 4
... N.C., Feb. 10, 2011 For the biopharmaceutical ... importance - and difficulty - of interacting with ... restrictions have created both opportunities and challenges for ... control. To help marketing teams in ...
... 3-V Biosciences, Inc. announced today Stephen R. Brady has ...   http://photos.prnewswire.com/prnh/20100513/LA04336LOGO ) "Steve,s contributions have been pivotal ... 3-V," said Merdad V. Parsey, MD, PhD, 3-V,s Chief Executive ... continue to build the 3-V team and advance the company,s ...
Cached Medicine Technology:Innovations in Patient-Focused Initiatives to Improve Outcomes 23-V Biosciences Promotes Stephen R. Brady to Chief Business Officer 2
(Date:9/18/2014)... CRDF Global released today its ... edition – rich with videos, images and interactive ... Global empowers scientists and innovators around the world. ... foundation and individual supporters, CRDF Global reaches across ... training and entrepreneurship. , The Annual Report highlights ...
(Date:9/18/2014)... 18, 2014 Phela Health and Wellness ... HABIT™ Program in South Africa. HABIT™ is a ... and distributed in South Africa by Bestflex. , Phela ... which has been tailored to address issues that are ... behavior modification and chronic disease prevention. This solution combines ...
(Date:9/18/2014)... 2014) A new expert panel report, Improving ... the Council of Canadian Academies, addresses the importance ... Each year about half of Canada,s seven million ... of this prescribing is done off-label (i.e. the ... health risks., Children have historically been excluded in ...
(Date:9/18/2014)... Dr. Andrea Basile, MD, one of the most ... at Basile Plastic Surgery to include Coolsculpting. This non-invasive technique ... in the world for the removal of fat because of ... Dr. Basile, Coolsculpting will greatly benefit those patients with body ... procedure. He also said this procedure is ideal for people ...
(Date:9/18/2014)... 18, 2014 The new BuildClean™ ... to contractors and homeowners alike as it eliminates ... the home, causes potential health issues, and makes ... the BuildClean system allows contractors to virtually eliminate ... other standard remodeling tasks. , BuildClean removes up ...
Breaking Medicine News(10 mins):Health News:CRDF Global Launches Media-Rich Digital Edition of Annual Report, Tells Story of Empowering Scientists and Innovators around the World in 2013 2Health News:Improving medicines for children in Canada 2Health News:Naples Plastic Surgeon Introduces Pain-free Fat Removal Technique 2Health News:Naples Plastic Surgeon Introduces Pain-free Fat Removal Technique 3Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 3Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 4
... Research Group is,an exciting newcomer in the field ... information service established to,provide the general public with ... choose for a variety of medical problems resulting ... the website will be,obtained through an online survey ...
... of the,Board and Chief Executive Officer, A.G. Lafley, addressed ... at its annual meeting today. Lafley,said, "P&G is a ... long term,-- consistently, reliably and sustainably." Growth in ... fiscal 2007. P&G increased,net sales by 12 percent to ...
... UPCARE(R) E2E, an end-to-end, financial and clinical ... for laboratories. -- ... Mich., Oct. 9 Today, UPCARE Technology, Inc.,unveiled its new ... part on the success of its parent company, Marquette,General Health ...
... three scientists receiving the 2007 Nobel Prize for Physiology or ... their careers, bringing to 42 the number of Nobel Laureates ... Capecchi, Ph.D. of the University of Utah and Oliver Smithies, ... with Sir Martin J. Evans of Cardiff University in Wales ...
... Nutrition,(OTC Bulletin Board: NNTN) http://www.interactivenutrition.com will ... 2007 at,11:00 a.m. Eastern time. U.S. and Canadian ... 800-750-4065 and International Shareholders may dial in at,404-920- ... 767872#. Executives,from Natural Nutrition will be available for ...
... Exchange Symbol: AKL, MONTREAL, Oct. 9 /PRNewswire-FirstCall/ ... company focused on developing therapies for the,inhalation, pain ... 2007, its issued and outstanding common shares will ... common share for every seven (7),pre-consolidation common shares. ...
Cached Medicine News:Health News:Nursesavvy.com Promoting Quality Healthcare for Everyone 2Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 2Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 3Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 4Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 5Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 6Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 2Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 3Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 4Health News:Natural Nutrition to Hold International Shareholder Conference Call Thursday, October 11, 2007 at 11:00 a.m. Eastern Time 2Health News:Akela Pharma Inc. Completes Share Consolidation 2
BioScrew® Bio-Absorbable Interference Screws and Delivery System Clinically equivalent to metal interference screws....
... Interference Screws. Optimal screw ... graft selection options. Robust ... deformation, and chamfered screw ... atraumatic tissue fixation. Features ...
Cannulated Interference Screws...
... on the TrueView II design, a new ... for small joint arthroscopy is available. The ... very durable thanks to Olympus advanced fibre ... class means bright images, brilliant colour reproduction, ...
Medicine Products: